Moomoo AI 已提取核心信息
Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, completed a sale of company stock on March 4, 2024. The transaction involved the disposal of 3,468 shares of common stock at a price of $11.1212 per share, resulting in a total sale value of $38,568.32. Following the sale, Moore's direct holdings in the company amount to 146,020 shares of common stock.
Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, completed a sale of company stock on March 4, 2024. The transaction involved the disposal of 3,468 shares of common stock at a price of $11.1212 per share, resulting in a total sale value of $38,568.32. Following the sale, Moore's direct holdings in the company amount to 146,020 shares of common stock.
Arcutis Biotherapeutics高级副总裁兼首席商务官马修·理查德·摩尔于2024年3月4日完成了公司股票的出售。该交易涉及以每股11.1212美元的价格出售3,468股普通股，总销售价值为38,568.32美元。出售后，摩尔在该公司的直接持有量为146,020股普通股。
Arcutis Biotherapeutics高级副总裁兼首席商务官马修·理查德·摩尔于2024年3月4日完成了公司股票的出售。该交易涉及以每股11.1212美元的价格出售3,468股普通股，总销售价值为38,568.32美元。出售后，摩尔在该公司的直接持有量为146,020股普通股。
有用
没用